- Home
- COYA vs TCRX Comparison
COYA vs TCRX Comparison
Compare COYA & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- TCRX
- Stock Information
- Founded
- COYA 2020
- TCRX 2018
- Country
- COYA United States
- TCRX United States
- Employees
- COYA N/A
- TCRX N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- COYA Health Care
- TCRX Health Care
- Exchange
- COYA Nasdaq
- TCRX Nasdaq
- Market Cap
- COYA 99.8M
- TCRX 82.1M
- IPO Year
- COYA 2022
- TCRX 2021
- Fundamental
- Price
- COYA $5.80
- TCRX $1.45
- Analyst Decision
- COYA Strong Buy
- TCRX Strong Buy
- Analyst Count
- COYA 3
- TCRX 6
- Target Price
- COYA $16.67
- TCRX $9.50
- AVG Volume (30 Days)
- COYA 52.1K
- TCRX 669.3K
- Earning Date
- COYA 08-11-2025
- TCRX 08-11-2025
- Dividend Yield
- COYA N/A
- TCRX N/A
- EPS Growth
- COYA N/A
- TCRX N/A
- EPS
- COYA N/A
- TCRX N/A
- Revenue
- COYA $3,685,107.00
- TCRX $4,421,000.00
- Revenue This Year
- COYA $106.97
- TCRX $159.20
- Revenue Next Year
- COYA N/A
- TCRX N/A
- P/E Ratio
- COYA N/A
- TCRX N/A
- Revenue Growth
- COYA N/A
- TCRX N/A
- 52 Week Low
- COYA $4.65
- TCRX $1.02
- 52 Week High
- COYA $10.24
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- COYA 55.18
- TCRX 46.44
- Support Level
- COYA $5.61
- TCRX $1.39
- Resistance Level
- COYA $5.87
- TCRX $1.73
- Average True Range (ATR)
- COYA 0.37
- TCRX 0.15
- MACD
- COYA 0.05
- TCRX -0.02
- Stochastic Oscillator
- COYA 67.51
- TCRX 12.53
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.